These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36874416)

  • 1. Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report.
    Yang R; Chen JX; Luo SH; Chen TT; Chen LW; Huang B
    World J Clin Cases; 2023 Feb; 11(5):1165-1174. PubMed ID: 36874416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report.
    Mao S; Zhang J; Guo Y; Zhang Z; Wu Y; Zhang W; Wang L; Geng J; Yan Y; Yao X
    Drug Des Devel Ther; 2019; 13():291-300. PubMed ID: 30666091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: Bladder preserving after maximal transurethral resection of the bladder tumor combined with chemotherapy and immunotherapy in recurrent muscle-invasive bladder cancer patients: A report of two cases.
    Mao J; Yang C; Xin S; Cui K; Liu Z; Wang T; Hu Z; Wang S; Liu J; Song X; Song W
    Front Med (Lausanne); 2022; 9():949567. PubMed ID: 35979208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer.
    Xu C; Zou W; Zhang L; Xu R; Li Y; Feng Y; Zhao R; Wang Y; Liu X; Wang J
    Front Immunol; 2023; 14():1162580. PubMed ID: 37283762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases.
    Li T; Hu W; Jin L; Yin X; Kang D; Piao L
    Front Oncol; 2023; 13():1164368. PubMed ID: 37124509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer.
    Nadal R; Apolo AB; Girardi DM; Hahn NM; Bellmunt J
    Urol Oncol; 2023 Jan; 41(1):27-34. PubMed ID: 34756410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study.
    Ren X; Tian Y; Wang Z; Wang J; Li X; Yin Y; Chen R; Zhan Y; Zeng X
    BMC Urol; 2022 Aug; 22(1):128. PubMed ID: 35987640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation.
    Khaled HM; Shafik HE; Zabhloul MS; Ghoneim M; Saber RA; Manie M; Enein HA; Megeed HA; Mansur O; Sherbini ME; Mahran TZ; Kalawee ME; Badran A; Ramadan SM
    Clin Genitourin Cancer; 2014 Oct; 12(5):e233-40. PubMed ID: 24889794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete response to pembrolizumab in a patient with recurrent and metastatic urothelial bladder carcinoma reflecting coexisting sarcomatoid subtype and glandular differentiation: a case report.
    Miyama Y; Kanao K; Uranishi K; Hirasaki M; Yasuda M
    Int Cancer Conf J; 2023 Jan; 12(1):24-30. PubMed ID: 36605848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: Successful treatment of advanced urothelial carcinoma with trophoblastic differentiation using Tislelizumab and Disitamab vedotin.
    Han Y; Zhou Y; Wu Z; Liu L; Han C
    Heliyon; 2024 Oct; 10(19):e38518. PubMed ID: 39397900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma.
    Du Z; Yin H; Zhao S; Ma Y; Sun Z; Dong B; Zhu M; Zhu C; Peng J; Yang T
    Front Oncol; 2022; 12():1062655. PubMed ID: 36620538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive urothelial carcinoma, lymphoma-like/plasmacytoid variant, successfully treated by radical cystectomy with adjuvant chemotherapy: a case report.
    Ohtaka M; Kawahara T; Kumano Y; Maeda Y; Kondo T; Mochizuki T; Ishida H; Hattori Y; Teranishi J; Miyoshi Y; Yumura Y; Yao M; Inayama Y; Uemura H
    J Med Case Rep; 2016 Mar; 10():48. PubMed ID: 26951070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors for urothelial carcinoma.
    Kim HS; Seo HK
    Investig Clin Urol; 2018 Sep; 59(5):285-296. PubMed ID: 30182073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report.
    Küronya Z; Danyi T; Balatoni T; Liszkay G; Tóth E; Biró K; Géczi L
    J Med Case Rep; 2022 Oct; 16(1):396. PubMed ID: 36316780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of urinary bladder urothelial carcinoma with squamous, glandular, and plasmacytoid differentiation.
    Makise N; Morikawa T; Takeshima Y; Homma Y; Fukayama M
    Case Rep Oncol; 2014 May; 7(2):362-8. PubMed ID: 24987357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 inhibitor toripalimab with gemcitabine as a neoadjuvant therapy for muscle-invasive bladder urothelial carcinoma: A case report.
    Yin H; Yongkang M; Bao G; Shiming Z; Chaohong H; Tiejun Y
    Medicine (Baltimore); 2022 Jan; 101(2):e28591. PubMed ID: 35029241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma.
    Patel A; Bisno DI; Patel HV; Ghodoussipour S; Saraiya B; Mayer T; Singer EA
    J Cancer Immunol (Wilmington); 2021; 3(2):115-136. PubMed ID: 34263255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urothelial Carcinoma Recurrence With an Ileal Conduit: Multimodal Management With Extirpative Surgery, Chemotherapy, and Immunotherapy.
    Thakker PU; Refugia J; Sandberg M; Rodriguez AR; Hemal AK
    Cureus; 2023 Dec; 15(12):e51157. PubMed ID: 38283476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.
    Witjes JA; Bruins HM; Cathomas R; Compérat EM; Cowan NC; Gakis G; Hernández V; Linares Espinós E; Lorch A; Neuzillet Y; Rouanne M; Thalmann GN; Veskimäe E; Ribal MJ; van der Heijden AG
    Eur Urol; 2021 Jan; 79(1):82-104. PubMed ID: 32360052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updates and novel treatments in urothelial carcinoma.
    Hanna KS
    J Oncol Pharm Pract; 2019 Apr; 25(3):648-656. PubMed ID: 30304985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.